mdpi.com/1718-7729/29/1…
we're finally in press -a very interesting literature review if you ever wondered how come we don't stratify adjuvant treatment according to the post-CTRT response

According to phase 3 findings, treatment w/ adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival vs observation & CRT for locally advanced nasopharyngeal carcinoma. JAMA Oncology #oncology ow.ly/b7WL50LmS7a

Cytoreductive nephrectomy associated with longer OS in patients with #mRCC treated with immune checkpoint inhibitor (ICI) therapy in any line of therapy. A multicenter retrospective cohort study of 367 patients (CN+ST 232, ST alone 135). sciencedirect.com/science/articl…

Our new study on HER2DX is out eBioMedicine – The Lancet Discovery Science

HER2DX validation in the PER-ELISA trial, evaluating neoadjuvant HP+letrozole in HR+/HER2+ breast cancer

bit.ly/3Nlxl5L

Hospital CLÍNIC IDIBAPS Universitat de Barcelona Università di Padova OncoAlert REVEAL GENOMICS

See the summary👇

How can the IARC World Cancer Report best serve the learning needs of oncology professionals in #cancerresearch for #cancerprevention ? Take the ESMO-IARC survey by 31 Oct. to help shape resource development according to your needs. ow.ly/KYqL50LiLob IARC ESMO - Eur. Oncology

Super ESOncology course on basic principles in #oncology …really grateful to these great guys for the kind invitation and the opportunity to meet many motivated young fellows from all over Europe 🥰💪🤩

fedro peccatori Alex Eniu, MD, PhD #EducationIsKey #UNIGEnonsiferma OncoAlert Università di Genova

Resistance to specific RET inhibitors is quite heterogeneous, with only 14% on-target resistance mechanisms. Large study in 100+ patients on primary and secondary resistance. It will not ease the development of 2nd gen inhibitors! #ENA2022 Mihaela Aldea Arianna Marinello

My people ♡ The unsung heroes

Amazing achievements in educational, care and research initiatives from #GeriOnc in Brazil leaded by Theodora Karnakis presented at #SIOG2022 . Model to be followed by middle-undeveloped countries with moxed private-public systems.SIOG SIOGNAH

Delighted to announce that the PRIMALUNG study comparing brain MR surveillance + PCI to brain MRI surveillance alone in patients with small cell lung cancer is now open to recruitment EORTC The Christie NHS Manchester Cancer Research Centre GustaveRoussy
See thread 👇🏽

Compelling arguments for neoadjuvant IO approach over adjuvant by Balazs Halmos Balazs Halmos at #DCLung22 in debate vs Benjamin Levy

In corso un interessante momento di confronto tra oncologi, ematologi e farmacisti sulla tematica dell’appropriatezza terapeutica guidata dall’approccio target-oriented in oncologia e oncoematologia al congresso #SIFO a Bologna

Undoubtedly ,the best online course on leadership in helathcare ♡

here the right link:
bit.ly/3SFL0pl

#ESMOBreast23 : Join us in Berlin or online to understand recent developments in novel diagnostics, biomarkers and treatments in #breastcancer , & more. Abstract submission system open – deadline 21 Feb 2023
ow.ly/lTHh50LmLiQ
#bcsm

Slide to print and keep close: drug interactions with ribociclib. Several commonly used drugs with high risk of interaction, including lansoprazole, ondansetron, ciprofloxacin & more. #PBCClive22

Two new interesting Press Releases in the MBC space: capivasertib (AKT inh) improved PFS in the phase 3 #CAPItello291 trial, & Camizestrant (SERD) improved PFS vs. Fulvestrant in the #SERENA2 ph 2 trial. Looking forward to seeing the magnitude of benefits.
astrazeneca.com/media-centre/p…

Excited to review the data at the upcoming meeting! Congrats to all involved. Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer | Business Wire businesswire.com/news/home/2022…

Another super clear round up from a great #ASTRO22 …thanks a lot Gil Morgan OncoAlert !